- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.04. | Navamedic ASA: NOTIFICATION OF MAJOR HOLDINGS | 1 | Oslo Børs | ||
| 21.03. | Disclosure in NAVAMEDIC ASA | 1 | Oslo Børs | ||
| 18.03. | Major shareholder disclosure in Navamedic ASA | - | Oslo Børs | ||
| 15.03. | Navamedic ASA - Mandatory notification of trade by primary insider | 1 | Cision News | ||
| 15.03. | Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options | - | Oslo Børs | ||
| 13.03. | Navamedic ASA: Navamedic welcomes new shareholders | 582 | PR Newswire | OSLO, Norway, March 13, 2024 /PRNewswire/ -- Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø... ► Artikel lesen | |
| 13.03. | Navamedic ASA - Notification of Major Holdings | 3 | Oslo Børs | ||
| 13.03. | Navamedic ASA: Notification of major shareholding and mandatory notification of trade | 301 | PR Newswire | OSLO, Norway, March 12, 2024 /PRNewswire/ -- Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were... ► Artikel lesen | |
| 12.03. | Contemplated block sale of existing shares in Navamedic ASA | 1 | Oslo Børs | ||
| 22.02. | Navamedic ASA: Mandatory notification of trade | 1 | Cision News | ||
| 15.02. | Navamedic ASA: Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives | 270 | PR Newswire | OSLO, Norway, Feb. 15, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced... ► Artikel lesen | |
| 13.02. | Navamedic ASA: Invitation to 2023 4th quarter presentation | 262 | PR Newswire | OSLO, Norway, Feb. 13, 2024 /PRNewswire/ -- Navamedic ASA (OSE: Nava) will be presenting its fourth quarter 2023 results on Thursday, February 15, 2024. The presentation will be held at Dronning... ► Artikel lesen | |
| 12.02. | Navamedic ASA launches Eroxon® | 1 | Cision News | ||
| 21.12.23 | Navamedic ASA: Renewed contract signed with Vitaflo International Limited | 354 | PR Newswire | OSLO, Norway, Dec. 21, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces... ► Artikel lesen | |
| 15.12.23 | Navamedic ASA: Financial calendar | - | Oslo Børs | ||
| 13.12.23 | Navamedic ASA: Navamedic and Orion Corporation sign non-binding term sheet for Flexilev®in Europe | 459 | PR Newswire | OSLO, Norway, Dec. 13, 2023 /PRNewswire/ -- Navamedic ASA and Orion Corporation ("Orion") have today signed a non-binding term sheet for a licensing- and supply agreement for Flexilev®, including... ► Artikel lesen | |
| 01.11.23 | Navamedic ASA: Record high quarter with above 50 percent growth | 362 | PR Newswire | OSLO, Norway, Nov. 1, 2023
/PRNewswire/ -- Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces... ► Artikel lesen | |
| 27.10.23 | Navamedic ASA: Invitation to 2023 3rd quarter presentation | 268 | PR Newswire | OSLO, Norway, Oct. 27, 2023 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) will be presenting its third quarter 2023 results on Wednesday, November 1, 2023. The presentation will be held at Haakon... ► Artikel lesen | |
| 30.08.23 | Navamedic ASA - Registration of share capital increase | 312 | PR Newswire | OSLO, Norway, Aug. 30, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement published on 18 August 2023 by Navamedic ASA (the "Company") regarding the board of directors'... ► Artikel lesen | |
| 18.08.23 | Navamedic ASA - Mandatory notification of trade by primary insider | 313 | PR Newswire | OSLO, Norway, Aug. 18, 2023 /PRNewswire/ -- Reference is made to the stock exchange announcement published earlier today, on 18 August 2023 by Navamedic ASA (the "Company" or "Navamedic")... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DERMAPHARM | 31,900 | +0,31 % | Dermapharm: Ein starkes Zeichen - Aktie zieht an | Die Dermapharm-Aktie kann sich am Mitttwoch weiter von ihren Tiefständen lösen und setzt ihren Aufwärtstrend fort. Besonders positiv wirkte sich die heutige Bekanntgabe eines Insiderkaufs aus. Ein bedeutender... ► Artikel lesen | |
| MPH HEALTH CARE | 21,000 | +7,14 % | EQS-News: MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände | EQS-News: MPH Health Care AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
MPH Health Care AG verkauft 1,5 Mio. Aktien ihrer Beteiligung M1 Kliniken AG an deren Vorstände... ► Artikel lesen | |
| CRONOS GROUP | 2,254 | +1,53 % | Cronos Group Inc. - 8-K, Current Report | ||
| ORGANIGRAM | 1,780 | +0,56 % | 50 - 200 % * X mit Cannabis Aktien? Aurora, Tilray, Organigram, Planet 13, High Tide, Village Farms | Sind Sie daran interessiert, in Cannabis-Aktien zu investieren, und fragen Sie sich nach den möglichen Renditen? In diesem Kommentar besprechen wir die Möglichkeit, mit Unternehmen wie Aurora Cannabis... ► Artikel lesen | |
| GRIFOLS | 8,254 | +0,44 % | Biotest baut aus, während Grifols weiter mit Gotham-Schatten kämpft. Ist die Mutter die spannendere Aktie? | Biotest hat in Wuppertal das 12. Plasmasammel-zentrum in Deutschland offiziell eröffnet. Klares Wachstumsprogramm ganz nach den Wünschen der Hauptaktionärin Grifols, die zuletzt von Shortsellern unter... ► Artikel lesen | |
| APONTIS PHARMA | 8,160 | -0,97 % | Original-Research: Apontis Pharma AG (von Montega AG): Kaufen | Original-Research: Apontis Pharma AG - von Montega AG Einstufung von Montega AG zu Apontis Pharma AG Unternehmen: Apontis Pharma AG ISIN: DE000A3CMGM5 Anlass der Studie: Update Empfehlung:... ► Artikel lesen | |
| BACHEM | 80,65 | -0,12 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.03.2024 - 4 | The following instruments on Boerse Frankfurt do have their last trading day on 14.03.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.03.2024ISIN NameCH0305285295 VARIA... ► Artikel lesen | |
| PHARMASGP | 22,400 | +1,82 % | PharmaSGP: "Prognose leicht übertroffen" | PharmaSGP meldet vorläufige Eckdaten für das Jahr 2023 - die komplette Bilanz 2023 soll am 29. April vorgelegt werden. Für das vergangene Jahr meldet das Pharma-Unternehmen aus Gräfelfing einen Umsatzanstieg... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 72,50 | -1,36 % | Cosmo Pharmaceuticals N.V.: Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care | Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 351,40 | +0,60 % | Ex-Dividend Reminder: Lennar, Lowe's And West Pharmaceutical | ||
| AZENTA | 47,200 | -0,84 % | Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023 | BURLINGTON, Mass., Feb. 7, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2023 .
Quarter... ► Artikel lesen | |
| POLYPEPTIDE GROUP | - | - | HAMLET BIOPHARMA AB: Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group | ||
| PHOTOCURE | 4,460 | -1,55 % | Photocure: European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care | OSLO, Norway, April 8, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the 2024 European... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 2,225 | -2,41 % | ArcticZymes Technologies ASA: ArcticZymes initiates joint research project with Austrian Centre of Industrial Biotechnology | ||
| ULTIMOVACS | 0,670 | +1,36 % | Ultimovacs - Steadfast commitment to UV1 progression | Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its... ► Artikel lesen |
NAVAMEDIC ASA gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
